title: Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma.
authors.affiliation: a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA ;
authors.forename: Chan Yoon
authors.initials: CY
authors.lastname: Cheah
authors.affiliation: a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA ;
authors.forename: Haleigh E
authors.initials: HE
authors.lastname: Mistry
authors.affiliation: b Department of Pathology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
authors.forename: Sergej
authors.initials: S
authors.lastname: Konoplev
authors.affiliation: a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA ;
authors.forename: Nathan H
authors.initials: NH
authors.lastname: Fowler
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000077269:Lenalidomide; D008214:Lymphocytes / Q000187:drug effects* / Q000473:pathology; D012074:Remission Induction; D000069283:Rituximab / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D000069283:Rituximab; D013792:Thalidomide; D000077269:Lenalidomide